Yahoo
PITTSBURGH, July 08, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, announced today that it has entered into a standby equity purchase agreement (“SEPA”) with YA II PN, LTD, an investment fund managed by Yorkville Advisors Global, LP (“Yorkville”). Predictive Oncology expects the partnership to provide an efficient and flexible source of funding, enabling the company to progress its ongoing drug discovery, biomarker discovery and drug repu
Yahoo
Models provide highly relevant species-specific data, predict in vivo drug clearance/transport, and support preclinical analysis of cancer therapiesPITTSBURGH, June 12, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, announced today the company has successfully developed 3D organoid models exclusively for Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services. As part of an ongoing agreement, Predictive Onco
Yahoo
PITTSBURGH, May 27, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, today issued the following statement regarding its dispute with Renovaro, Inc. Contrary to a press release issued by RENB, the Delaware Court of Chancery recently rejected RENB’s request for an expedited, two-day trial in July. The Court reached this decision citing RENB’s delay in bringing its action. POAI fully intends to protect its rights and defend against the claims a
Yahoo
LOS ANGELES, May 22, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced that it has received a ruling to expedite a trial in 2025 for the lawsuit it filed on May 9, 2025, in the Delaware Court of Chancery against Predictive Oncology Inc. (NASDAQ: POAI), seeking to enforce a binding merger agreement executed on January 1, 2025. According to the Verified Complaint
Yahoo
LOS ANGELES, May 22, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced that it has received a ruling to expedite a trial in 2025 for the lawsuit it filed on May 9, 2025, in the Delaware Court of Chancery against Predictive Oncology Inc. (NASDAQ: POAI), seeking to enforce a binding merger agreement executed on January 1, 2025. According to the Verified Complaint
Yahoo
Company Leverages More Than Twenty Years of Drug Response Data Derived from Massive Biobank of Live Cell Tumor SamplesPITTSBURGH, May 22, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) moves to leverage its vast biobank of more than 150,000 heterogenous live cell tumor samples and drug response data to aggressively pursue novel drug discovery, biomarker discovery and drug repurposing using AI and machine learning. Earlier this week, Regeneron Pharmaceuticals announced its acqui
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTAL | -20.91% | $315.93M | 1.43% |
TBLL | -13.94% | $2.12B | 0.08% |
TAIL | -13.33% | $94.86M | 0.59% |
IVOL | -12.05% | $342.69M | 1.02% |
BIL | -12.00% | $41.93B | 0.1356% |
XBIL | -11.93% | $784.60M | 0.15% |
GBIL | -11.60% | $6.36B | 0.12% |
VIXY | -11.58% | $184.73M | 0.85% |
SPTS | -8.90% | $5.77B | 0.03% |
IBTH | -8.88% | $1.62B | 0.07% |
UTWO | -8.54% | $376.33M | 0.15% |
SHV | -7.92% | $20.59B | 0.15% |
GOVT | -7.84% | $27.25B | 0.05% |
IYK | -7.66% | $1.44B | 0.4% |
SMIN | -7.55% | $935.63M | 0.75% |
XONE | -7.48% | $628.85M | 0.03% |
XHLF | -7.43% | $1.73B | 0.03% |
STPZ | -7.39% | $443.27M | 0.2% |
REZ | -7.12% | $785.71M | 0.48% |
IBTG | -6.90% | $1.92B | 0.07% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CBZ | -0.02% | $3.98B | -2.96% | 0.00% |
SPWH | -0.02% | $143.69M | +60.60% | 0.00% |
IRM | 0.03% | $29.20B | +4.70% | 3.06% |
CODI | 0.05% | $495.81M | -70.87% | 15.44% |
NVGS | -0.06% | $1.06B | -9.53% | 1.30% |
PAYX | 0.06% | $52.34B | +24.13% | 2.76% |
ZCMD | 0.06% | $28.54M | -8.87% | 0.00% |
HEI.A | 0.07% | $33.67B | +35.55% | 0.09% |
EQX | -0.07% | $4.64B | +2.17% | 0.00% |
TAL | -0.08% | $4.86B | -1.22% | 0.00% |
CWST | 0.09% | $7.05B | +9.30% | 0.00% |
TRS | 0.09% | $1.22B | +18.90% | 0.54% |
HSY | 0.10% | $33.36B | -11.86% | 3.35% |
MFA | -0.10% | $973.15M | -15.66% | 15.07% |
PCG | -0.12% | $29.76B | -24.61% | 0.63% |
PAAS | 0.12% | $10.63B | +22.25% | 1.34% |
CVM | -0.12% | $20.33M | -89.73% | 0.00% |
STTK | -0.12% | $37.09M | -80.88% | 0.00% |
CSTL | 0.13% | $572.83M | +7.30% | 0.00% |
NTZ | -0.13% | $33.60M | -33.39% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
GOVZ | 0.01% | $265.96M | 0.1% |
BKAG | 0.01% | $1.91B | 0% |
BOND | -0.06% | $5.60B | 0.7% |
LVHD | -0.08% | $568.15M | 0.27% |
GCOR | 0.08% | $588.82M | 0.08% |
SCHZ | 0.10% | $8.54B | 0.03% |
GLTR | -0.10% | $1.45B | 0.6% |
BND | -0.15% | $130.65B | 0.03% |
EAGG | -0.15% | $3.96B | 0.1% |
BBRE | -0.16% | $913.89M | 0.11% |
TDTT | 0.16% | $2.63B | 0.18% |
MSOS | -0.18% | $343.11M | 0.77% |
SCHP | -0.18% | $12.94B | 0.03% |
BSCT | 0.19% | $2.12B | 0.1% |
WEAT | -0.20% | $123.28M | 0.28% |
BOXX | 0.22% | $6.93B | 0.19% |
SPRE | -0.24% | $158.25M | 0.5% |
BSCU | -0.25% | $1.65B | 0.1% |
BSCP | -0.27% | $3.25B | 0.1% |
INDA | 0.28% | $10.07B | 0.62% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
LTM | 50.51% | $12.85B | -95.43% | 2.39% |
FUBO | 40.86% | $1.19B | +173.23% | 0.00% |
VMI | 30.69% | $6.83B | +25.75% | 0.75% |
NTCT | 29.67% | $1.61B | +22.54% | 0.00% |
NOW | 29.53% | $200.54B | +29.23% | 0.00% |
LPX | 29.16% | $6.71B | +14.63% | 1.13% |
SYPR | 27.98% | $48.49M | +14.05% | 0.00% |
FBIO | 27.83% | $58.84M | +1.02% | 0.00% |
WPRT | 27.54% | $56.49M | -48.42% | 0.00% |
RES | 27.35% | $1.15B | -12.01% | 3.09% |
GSHD | 27.09% | $2.52B | +78.85% | 0.00% |
MCRI | 27.02% | $1.65B | +30.24% | 1.34% |
CRNC | 26.99% | $423.06M | +206.58% | 0.00% |
VC | 26.97% | $2.95B | -0.40% | 0.00% |
ABCL | 26.61% | $1.27B | +35.78% | 0.00% |
WH | 26.57% | $6.88B | +22.42% | 1.78% |
DOV | 26.46% | $26.12B | +4.62% | 1.09% |
RS | 26.18% | $17.49B | +13.73% | 1.39% |
WFG | 25.60% | $6.18B | +0.32% | 1.66% |
FBNC | 25.31% | $1.95B | +34.44% | 1.91% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
ARKG | 24.11% | $1.03B | 0.75% |
PBW | 23.74% | $294.50M | 0.65% |
ACES | 22.46% | $97.20M | 0.55% |
WCLD | 22.34% | $377.26M | 0.45% |
QCLN | 22.22% | $415.53M | 0.56% |
SLX | 22.09% | $78.66M | 0.56% |
PBD | 21.78% | $75.55M | 0.75% |
BATT | 21.78% | $62.34M | 0.59% |
IPO | 21.74% | $142.25M | 0.6% |
IDRV | 21.16% | $152.69M | 0.47% |
ARKK | 21.05% | $6.81B | 0.75% |
ERTH | 21.02% | $137.44M | 0.67% |
XTN | 20.81% | $174.94M | 0.35% |
ARKQ | 20.63% | $1.09B | 0.75% |
XSW | 20.51% | $509.81M | 0.35% |
KOMP | 20.50% | $2.34B | 0.2% |
ARKX | 20.19% | $344.77M | 0.75% |
FRDM | 20.00% | $1.22B | 0.49% |
ROBT | 19.84% | $510.97M | 0.65% |
SKYY | 19.79% | $3.54B | 0.6% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
EW | -36.26% | $46.22B | -15.13% | 0.00% |
CL | -19.84% | $73.44B | -7.30% | 2.25% |
CRMD | -18.70% | $871.57M | +138.49% | 0.00% |
ALL | -17.80% | $51.55B | +20.14% | 1.98% |
WM | -16.72% | $90.80B | +6.55% | 1.40% |
LKQ | -16.41% | $10.12B | -8.09% | 3.09% |
PG | -16.17% | $371.59B | -4.26% | 2.59% |
CHD | -16.09% | $24.40B | -4.48% | 1.17% |
INVH | -16.09% | $19.85B | -8.63% | 3.59% |
DUK | -15.89% | $91.85B | +13.12% | 3.57% |
FPI | -15.75% | $510.49M | -3.25% | 2.18% |
SO | -15.46% | $102.50B | +16.78% | 3.13% |
WEC | -14.74% | $33.73B | +31.54% | 3.27% |
GTX | -14.74% | $2.33B | +28.38% | 1.05% |
OHI | -14.55% | $10.61B | +6.51% | 7.33% |
RSG | -14.50% | $75.03B | +20.83% | 0.97% |
ROL | -14.50% | $26.96B | +12.66% | 1.16% |
ORN | -14.15% | $342.14M | -1.37% | 0.00% |
CNX | -13.73% | $4.82B | +28.19% | 0.00% |
GIS | -13.55% | $27.86B | -18.70% | 5.88% |
Current Value
$0.811 Year Return
Current Value
$0.811 Year Return